OBJECTIVE: To review a novel approach for constructing composite response criteria for use in chronic gout clinical trials that implements a method of multicriteria decision-making. METHODS: Preliminary work with paper patient profiles led to a restricted set of core-set domains that were examined using 1000Minds™ by rheumatologists with an interest in gout, and (separately) by OMERACT registrants prior to OMERACT 10. These results and the 1000Minds approach were discussed during OMERACT 10 to help guide next steps in developing composite response criteria. RESULTS: There were differences in how individual indicators of response were weighted between gout experts and OMERACT registrants. Gout experts placed more weight upon changes in uric acid levels, whereas OMERACT registrants placed more weight upon reducing flares. Discussion highlighted the need for a "pain" domain to be included, for "worsening" to be an additional level within each indicator, for a group process to determine the decision-making within a 1000Minds exercise, and for the value of patient involvement. CONCLUSION: Although there was not unanimous support for the 1000Minds approach to inform the construction of composite response criteria, there is sufficient interest to justify ongoing development of this methodology and its application to real clinical trial data.
OBJECTIVE: To review a novel approach for constructing composite response criteria for use in chronic gout clinical trials that implements a method of multicriteria decision-making. METHODS: Preliminary work with paper patient profiles led to a restricted set of core-set domains that were examined using 1000Minds™ by rheumatologists with an interest in gout, and (separately) by OMERACT registrants prior to OMERACT 10. These results and the 1000Minds approach were discussed during OMERACT 10 to help guide next steps in developing composite response criteria. RESULTS: There were differences in how individual indicators of response were weighted between gout experts and OMERACT registrants. Gout experts placed more weight upon changes in uric acid levels, whereas OMERACT registrants placed more weight upon reducing flares. Discussion highlighted the need for a "pain" domain to be included, for "worsening" to be an additional level within each indicator, for a group process to determine the decision-making within a 1000Minds exercise, and for the value of patient involvement. CONCLUSION: Although there was not unanimous support for the 1000Minds approach to inform the construction of composite response criteria, there is sufficient interest to justify ongoing development of this methodology and its application to real clinical trial data.
Authors: Nicola Dalbeth; Cathy S Zhong; Rebecca Grainger; Dinesh Khanna; Puja P Khanna; Jasvinder A Singh; Fiona M McQueen; William J Taylor Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Jasvinder A Singh; William J Taylor; Nicola Dalbeth; Lee S Simon; John Sundy; Rebecca Grainger; Rieke Alten; Lyn March; Vibeke Strand; George Wells; Dinesh Khanna; Fiona McQueen; Naomi Schlesinger; Annelies Boonen; Maarten Boers; Kenneth G Saag; H Ralph Schumacher; N Lawrence Edwards Journal: J Rheumatol Date: 2013-12-15 Impact factor: 4.666
Authors: Rohit Aggarwal; Lisa G Rider; Nicolino Ruperto; Nastaran Bayat; Brian Erman; Brian M Feldman; Chester V Oddis; Anthony A Amato; Hector Chinoy; Robert G Cooper; Maryam Dastmalchi; David Fiorentino; David Isenberg; James D Katz; Andrew Mammen; Marianne de Visser; Steven R Ytterberg; Ingrid E Lundberg; Lorinda Chung; Katalin Danko; Ignacio García-De la Torre; Yeong Wook Song; Luca Villa; Mariangela Rinaldi; Howard Rockette; Peter A Lachenbruch; Frederick W Miller; Jiri Vencovsky Journal: Ann Rheum Dis Date: 2017-05 Impact factor: 19.103
Authors: Carlo A Scirè; Greta Carrara; Cinzia Viroli; Marco A Cimmino; William J Taylor; Maria Manara; Marcello Govoni; Fausto Salaffi; Leonardo Punzi; Carlomaurizio Montecucco; Marco Matucci-Cerinic; Giovanni Minisola Journal: Arthritis Care Res (Hoboken) Date: 2016-09-06 Impact factor: 4.794